design:
  num_vhh_designs: 10
  num_fab_designs: 10
  target_structures:
  - data/targets/1XIW.pdb
  - data/targets/1SY6.pdb
  fab_scaffolds:
  - adalimumab
  - belimumab
  - dupilumab
  - golimumab
  - guselkumab
  - necitumumab
  - nirsevimab
  - sarilumab
  - secukinumab
  - tezepelumab
  - tralokinumab
  - ustekinumab
  fab_scaffold_dir: data/fab_scaffolds
  starting_sequences:
  - teplizumab
  - sp34
  - ucht1
  affinity_variants:
  - wild_type
  - 10x_weaker
  - 100x_weaker
calibration:
  positive_controls:
  - teplizumab
  - sp34
  - ucht1
  pdockq_margin: 0.05
  interface_area_margin: 100
  contacts_margin: 2
filtering:
  min_pdockq: 0.5
  min_interface_area: 800
  min_contacts: 10
  use_calibrated: true
  min_oasis_score: 0.8
  generate_back_mutations: true
  allow_deamidation_cdr: false
  allow_isomerization_cdr: false
  allow_glycosylation_cdr: false
  max_oxidation_sites: 2
  cdr_h3_length_range:
  - 8
  - 20
  net_charge_range:
  - -2
  - 4
  pi_range:
  - 6.0
  - 9.0
  max_hydrophobic_patches: 2
  min_candidates: 10
  relax_soft_filters_first: true
  max_threshold_relaxation: 0.1
formatting:
  tumor_target: trastuzumab
  formats:
  - crossmab
  - fab_scfv
  - fab_vhh
  - igg_scfv
  - igg_vhh
  scfv_linker: GGGGSGGGGSGGGGS
  fc_fusion_linker: GGGGSGGGGS
output:
  num_final_candidates: 10
  include_structures: true
  generate_report: true
  include_provenance: true
  output_dir: data/outputs
reproducibility:
  boltzgen_seed: 42
  sampling_seed: 12345
  clustering_seed: 0
epitope:
  okt3_epitope_residues: null
  overlap_threshold: 0.5
calibrated_thresholds:
  min_pdockq: 0.0
  min_interface_area: 2060.0
  min_contacts: 28
